Gomez-Abuin Gonzalo, Karam Aída Amelia, Mezzadri Norberto Aristídes, Bas Carlos Arturo
Section of Clinical Oncology, Hospital Alemán, Buenos Aires, Argentina.
Clin Genitourin Cancer. 2009 Jan;7(1):62-3. doi: 10.3816/CGC.2009.n.011.
A 62-year-old woman was treated with sunitinib as a second-line therapy for metastatic clear-cell renal carcinoma. She was given oral sunitinib 50 mg once daily, 4 weeks on followed by 2 week off. During the fourth week of her first cycle, the patient was admitted to our hospital because of an acute-onset, right upper quadrant pain associated with nausea and vomiting. She was diagnosed with acute acalculous cholecystitis, which was treated with broad-spectrum antibiotics, and sunitinib therapy was discontinued. A follow-up computed tomography scan of the abdomen revealed a complete resolution of gallbladder changes. Our patient did not have major risk factors for developing an acalculous cholecystitis except for a relative immunosuppressed state secondary to her advanced renal cancer. The Naranjo Adverse Drug Reaction Probability Scale score for this event was 5, indicating a probable association of the event with sunitinib. Because the use of sunitinib is expanding in clinical practice, we want to alert the oncology community about this uncommon and life-threatening complication in patients receiving sunitinib or another agent with antiangiogenic activity.
一名62岁女性接受舒尼替尼治疗，作为转移性透明细胞肾癌的二线治疗方案。她每天口服一次50毫克舒尼替尼，服药4周后停药2周。在第一个周期的第四周，患者因突发右上腹疼痛并伴有恶心、呕吐入住我院。她被诊断为急性非结石性胆囊炎，接受了广谱抗生素治疗，舒尼替尼治疗中断。腹部后续计算机断层扫描显示胆囊病变完全消退。除了因晚期肾癌导致的相对免疫抑制状态外，我们的患者没有发生非结石性胆囊炎的主要危险因素。该事件的Naranjo药物不良反应概率量表评分为5分，表明该事件可能与舒尼替尼有关。由于舒尼替尼在临床实践中的应用正在扩大，我们希望提醒肿瘤学界注意接受舒尼替尼或其他具有抗血管生成活性药物治疗的患者中这种罕见且危及生命的并发症。
